Genomic Health today announced the publication of an updated assessment of breast cancer gene expression profiling tests by the German Institute for Quality and Efficiency in Health Care (IQWiG). In their analysis, IQWiG concluded that, based on results from the TAILORx study, the Oncotype DX Breast Recurrence Score® test can support patients with primary node-negative, hormone-receptor-positive, HER2-negative breast cancer in the decision for or against chemotherapy.
IQWiG’s technical assessment will inform the Federal Joint Committee (G-BA) official reimbursement procedure. In July 2018, the G-BA publicly stated that a final decision on reimbursement of breast cancer gene expression profiling tests is expected by the end of 2018.
“With IQWiG’s recognition of the unique value the Oncotype DX test provides, we believe we are one step closer to ensuring reimbursed access to tens of thousands of breast cancer patients diagnosed in Germany each year as is the case in other countries around the world including the U.S., Canada, the UK, France, Spain and Switzerland,” said Torsten Hoof, Senior Vice President International, Genomic Health. “We look forward to G-BA’s final reimbursement decision later this year as we continue to see the impact of the landmark TAILORx study results on clinical practice around the world.”
IQWiG’s conclusion is based on results from TAILORx, the largest randomized adjuvant breast cancer treatment trial ever conducted that were recently published in The New England Journal of Medicine. This independently-conducted, prospective, phase III study followed more than 10,000 women with node-negative, hormone-receptor positive (HR+), HER2-negative early breast cancer for an average of nine years.
Study results demonstrate that the Oncotype DX Breast Recurrence Score test provides definitive long-term evidence about the magnitude of chemotherapy benefit, identifying the vast majority of women with early-stage breast cancer who receive no significant benefit from chemotherapy, as well as the important minority of women for whom chemotherapy can be life-saving. Thus, the test can greatly reduce both over- and undertreatment with chemotherapy.
Oncotype DX is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer. Breast cancer is the most common cancer in European women and affects many of them during their years dedicated to working and raising a family. While chemotherapy is routinely offered, research shows that only a minority of patients with early-stage breast cancer actually benefit from it.
The Oncotype DX test is designed to facilitate personalized clinical decisions by providing information about the biology of an individual breast cancer, with the potential to deliver financial benefits for healthcare systems. This is supported by substantial real-world evidence showing that the test can reduce the number of women undergoing unnecessary chemotherapy by up to 60 percent.
Healthcare systems across Europe are recognizing the value of the test, which is incorporated in all major international clinical guidelines. Following assessment and recommendation by NICE, the Oncotype DX test is widely available to patients across the UK. In France, Oncotype DX is available through a funding mechanism for genomic tests. Other European countries where the test is reimbursed include Switzerland, Ireland, Greece and Spain.
1. Sparano et al. New Engl J Med. 2018 Jul 12;379(2):111-121
2. EUCAN. 2012. Available at: http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2
3. Paik et al. J Clin Oncol. 2006; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Lancet. 2012.
4. Loncaster J et al, Eur J Surg Oncol 2017